AMS BioteQ
AMS BioteQ is a Taiwan-based biotechnology company (est. 2018) focused on antimicrobial research, medical-material development and natural-product drug discovery. The company develops wound dressings (foam, hydrogel, gelatin) that incorporate natural antimicrobial ingredients, pursues antiviral and anti-tumor small-molecule programs, manages an active patent portfolio, and has pursued regulatory approvals and international distribution for its medical materials.
Industries
Nr. of Employees
small (1-50)
AMS BioteQ
7F.-2, No. 6, Siwei 3rd Rd., Lingya Dist., Kaohsiung City 802, Taiwan (R.O.C.)
Patents
Artificial dressing and use of artificial dressing for promoting wound healing
US-11969518-B2
View Details
Artificial dressing and use of artificial dressing for promoting wound healing
US-11969518-B2
View DetailsProducts
Antimicrobial-integrated wound dressings (foam/hydrogel/gelatin formats)
Absorbent wound dressings formulated with natural antimicrobial ingredients designed to maintain moist healing, absorb exudate and promote tissue regeneration; supported by preclinical animal model data.
Natural-product antiviral drug candidates
Preclinical plant-derived small-molecule programs developed for antiviral activity and low residual toxicity; subject to in vitro and preclinical evaluation.
Antimicrobial-integrated wound dressings (foam/hydrogel/gelatin formats)
Absorbent wound dressings formulated with natural antimicrobial ingredients designed to maintain moist healing, absorb exudate and promote tissue regeneration; supported by preclinical animal model data.
Natural-product antiviral drug candidates
Preclinical plant-derived small-molecule programs developed for antiviral activity and low residual toxicity; subject to in vitro and preclinical evaluation.
Expertise Areas
- Wound care materials and dressing development
- Antimicrobial substance discovery and formulation
- Antiviral small-molecule discovery
- Oncology drug research and nanoparticle delivery
Key Technologies
- Hydrogel and foam dressing materials
- Natural product extraction and fractionation
- Composite dressing materials with controlled antimicrobial release
- Nanoparticle drug-delivery systems
News & Updates
Signed a memorandum of understanding to provide internships and scholarships and to foster collaboration on pharmaceutical research talent cultivation.
Exhibited antiviral plant-based drug research and novel anti-tumor therapies at CPHI Japan; reported plans to seek permits and expand in Japan.
Presented absorbent wound-dressing product line at an international event supporting Ukraine reconstruction; reported animal-model evidence for wound healing and tissue regeneration.
Announcement of Class I medical device sales authorization in Japan for two foam wound dressing products.
Reported registration with the U.S. FDA for a foam wound-dressing product.
Reported receipt of TFDA medical device approval for a foam dressing product.
Signed a memorandum of understanding to provide internships and scholarships and to foster collaboration on pharmaceutical research talent cultivation.
Exhibited antiviral plant-based drug research and novel anti-tumor therapies at CPHI Japan; reported plans to seek permits and expand in Japan.
Presented absorbent wound-dressing product line at an international event supporting Ukraine reconstruction; reported animal-model evidence for wound healing and tissue regeneration.
Announcement of Class I medical device sales authorization in Japan for two foam wound dressing products.
Reported registration with the U.S. FDA for a foam wound-dressing product.
Reported receipt of TFDA medical device approval for a foam dressing product.